PDCD1 and neoplasm: Tislelizumab can activate multiple signaling pathways in the body, contributing to an immunosuppressive tumor microenvironment state.19,20 The PD-1/PD-L1 signaling pathway can activate T cell proliferation and cytokine generation and exert an inhibitory effect that eventually allows cancer immune escape.19–21